Dr. Alexander Eggermont: The New Era of Melanoma Research

(00:10:52) EJC News Focus, 2011 Jul 1

The July issue of EJC News Focus is an interview with our editor-in-chief, melanoma expert Alexander Eggermont. Advances in the treatment of melanoma stole the limelight at the recent ASCO Annual meeting; after decades of unsuccessful research, data was presented showing that two drugs with completely different mechanisms of action – ipilimumab and vemurafenib – could improve overall survival in advanced disease. EJC News Focus explores these and the other developments in the pipeline that look set to usher in a new era in melanoma research.

See related videos to:
EJC News Focus

Related Links:

Viewpoints: Dr. Paul Chapman: Exciting Times Ahead—Things Are Changing Very Quickly in Melanoma Research »
News Article: Melanoma Treatment Ipilimumab Approved Europe-Wide »
Journal Scans: Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma »
Videos: Ipilimumab for Metastatic Melanoma: What Clinicians Should Know About the Drug and Its Effects »
Journal Scans: Inhibition of Mutated, Activated BRAF in Metastatic Melanoma »
Journal Scans: KIT as a Therapeutic Target in Metastatic Melanoma »